Novel prolonged-release polymeric particles for relief of intractable neuropathic pain
Minze Zhu · The University of Queensland · 2020
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
The University of Queensland · The University of Queensland · dissertation · 2020
Abstract
For severe cancer-related pain that is not relieved adequately by escalating doses of oral or parenterally administered strong opioid analgesics such as hydromorphone, alone or in combination with an adjuvant drug such as ketamine, more invasive dosing routes may be warranted. One such approach involves surgical implantation of an intrathecal pump to deliver small doses of analgesic and/or adjuvant drugs in close proximity to the receptors that transduce their pain-relieving effects. However, the use of implanted devices is associated with a range of catheter-related problems.
To address this, my PhD research explored the use of biocompatible, bioerodable polymers to encapsulate analgesic/adjuvant drugs to produce prolonged release formulations for injection into the cerebrospinal fluid of the spinal cord in close proximity to the drug targets of interest. This approach was aimed at producing prolonged release particles of each of the encapsulated drugs following a single i.t. injection of hydromorphone and ketamine particles in combination.The first aim of my PhD research project was to prepare ketamine-loaded poly (lactic-co-glycolic acid) (PLGA) microparticles using a dissolvable hydrogel template method.
Briefly, using PLGA with three different ratios of lactic acid to glycolic acid (L/G) as encapsulating material, relatively high ketamine-loading microparticles with homogenous particle shape and size were achieved. Specifically, ketamine loading of PLGA5050, PLGA7525 and PLGA8515 in ester-terminated microparticles was 20.0%, 20.4% and 18.9%, respectively. This is nearly threefold higher than previously observed using a water/oil/water (w/o/w) double emulsion method.
The microparticles were within the desired size range (20 μm diameter and 30 μm height) and in vitro release was sustained for ≥ 14 days with an acceptable initial burst release (~10-20%) achieved.Next, to potentially improve the initial burst and achieve a sustained in vitro release over 28 days period, bulk erosion and surface eroding polymers, and their mixtures, were investigated for optimal drug loading and sustained release profile. Ketamine- or hydromorphone-loaded polymer-core lipid-shell hybrid nanoparticles (NPs) with tunable size (400-500 nm) were fabricated with high encapsulation efficiency (EE, 60% ~ 80%) using a two-stage microfluidic process.
The in vitro release from ketamine-loaded NPs produced with a polymer mixture (sebacic acid (SA) and 1,3-bis(p-carboxyphenoxy) propane(CPP), CPP-SA/PLGA 50:50) was highly desirable, with 15.6% released within 3 h and a steady release of up to 92% achieved over a 28 day period. For hydromorphone-loaded NPs, 19.0% was released in the first 3 h and a sustained release to 51.5% over 28 days was achieved.The final aim of my PhD research project was to conduct a pilot study in chronic constriction injury (CCI) rats to assess the analgesic efficacy profile of i.t. bolus co-injection of hydromorphone‐loaded and ketamine-loaded lipid hybrid NPs.
In brief, nerve injury induced CCI-rats with fully developed mechanical allodynia in the ipsilateral hind paws were anesthetized deeply with 3% isoflurane in oxygen, to facilitate surgical implantation of a polyethylene cannula (OD, 0.61 mm, ID, 0.28 mm) into the lumbar i.t. space. Four days later, rats received an i.t. bolus dose of hydromorphone alone or in combination with ketamine, relative to vehicle. Ipsilateral hind paw PWTs were assessed immediately pre-dose and every 30 min post dosing until 5 h using von Frey filaments.
For analgesic efficacy assessment of NPs, anesthetized CCI-rats were administered an i.t. dose of hydromorphone-loaded NPs at 50 µg in combination with ketamine-loaded NPs (340 µg) or vehicle. Ipsilateral hind paw PWTs were assessed immediately pre-dose and at 3, 6, 24, 30, 48, 54, 72, 78 and 96 h post-dosing. The analgesia was evoked by the i.t. bolus co-injection of hydromorphone‐loaded and ketamine-loaded lipid hybrid NPs (50 µg and 340 µg respectively) within 3 h with a duration of action of 72 h. However, the extent and duration of pain relief did not differ significantly from that evoked by i.t. injection of sustained-release hydromorphone-loaded NPs (50 µg) alone in CCI-rats.
Together our in vivo findings suggested that the amount of ketamine released into the spinal cerebrospinal fluid after a bolus i.t. dose of ketamine-loaded NPs at 340 µg was likely insufficient to augment hydromorphone-evoked analgesia or to prevent the development of analgesic tolerance to hydromorphone at 50 µg in CCI-rats. Future work could further investigate a range of i.t. doses of sustained-release ketamine NPs co-injected with hydromorphone NPs for relief of intractable neuropathic pain.
Open the resolved locator · 10.14264/77aedff
Metadata licence: OpenAlex metadata (CC0)